YBR238C Antibody

What is YBR238C and why is it significant for aging research?

YBR238C is an uncharacterized yeast gene that has emerged as a significant regulator of chronological and replicative lifespan in Saccharomyces cerevisiae. The gene product is a 731-amino acid protein with an intrinsically unstructured region over the first ~130 residues, followed by a pentatricopeptide repeat region (residues 130-675) . The significance of YBR238C in aging research stems from its identification as the only uncharacterized gene that is both downregulated by rapamycin and demonstrates increased chronological lifespan (CLS) and replicative lifespan (RLS) upon deletion . This positions YBR238C as a critical node connecting TORC1 inhibition with increased cellular longevity, making it an attractive target for researchers studying fundamental mechanisms of aging and age-related diseases .

How does YBR238C influence mitochondrial function?

YBR238C negatively regulates mitochondrial function through both HAP4-dependent and HAP4-independent mechanisms. Deletion of YBR238C increases the expression of HAP4, a transcription factor that controls the expression of mitochondrial electron transport chain components . Transcriptome analysis of ybr238cΔ mutants reveals upregulation of genes related to mitochondrial energy metabolism, particularly electron transport chain (ETC) complexes I-V . Consequently, ybr238cΔ cells demonstrate enhanced mitochondrial respiration, higher ATP levels, and lower reactive oxygen species (ROS) production compared to wild-type cells . Conversely, YBR238C overexpression induces mitochondrial dysfunction, characterized by decreased respiratory capacity and increased ROS levels, accelerating cellular aging .

What epitopes of YBR238C are most suitable for antibody development?

When developing antibodies against YBR238C, researchers should consider the protein's structural features. The sequence architecture analysis reveals an intrinsically unstructured region over the first ~130 residues (including a histidine/asparagine-rich region beginning at position 83) and a pentatricopeptide repeat region (residues 130-675) . For antibody development, the most suitable epitopes would typically be in the more structured regions of the protein, particularly within the pentatricopeptide repeat domain, which is likely involved in RNA binding similar to its paralog RMD9 . When designing immunogens, avoid the unstructured N-terminal region, as these regions often produce antibodies with lower specificity and higher cross-reactivity.

How can researchers distinguish between YBR238C and its paralog RMD9 in experimental settings?

Distinguishing between YBR238C and its paralog RMD9 presents a significant challenge due to their shared pentatricopeptide repeat domains and potential functional overlap . To develop antibodies with high specificity for YBR238C over RMD9, researchers should:

• Target unique epitopes outside the conserved pentatricopeptide repeat region

• Perform thorough cross-reactivity testing against both proteins

• Validate antibody specificity using knockout controls (ybr238cΔ and rmd9Δ strains)

A robust validation protocol should include Western blot analysis comparing wild-type, ybr238cΔ, rmd9Δ, and double knockout strains. Additionally, consider using epitope-tagged versions of both proteins to establish clear molecular weight differences and confirm antibody specificity . This distinction is particularly important given the antagonistic effects of these paralogs on mitochondrial function and cellular aging .

What are the methodological considerations for tracking YBR238C protein localization changes under TORC1 inhibition?

Tracking YBR238C localization changes in response to TORC1 inhibition requires careful experimental design due to the complex regulatory relationship between TORC1, YBR238C, and mitochondrial function. The research indicates that YBR238C is transcriptionally upregulated by TORC1 activity and downregulated by rapamycin treatment . To investigate localization changes:

Critical controls should include rapamycin-treated vs. untreated cells, comparison with localization patterns of established mitochondrial markers, and validation using ybr238cΔ strains to confirm antibody specificity . Additionally, time-course experiments following rapamycin treatment would provide insights into the kinetics of YBR238C translocation and its relationship to changes in mitochondrial function.

How can antibodies be used to investigate the antagonistic relationship between YBR238C and RMD9?

The antagonistic relationship between YBR238C and RMD9 represents a fascinating aspect of mitochondrial regulation and cellular aging . YBR238C overexpression and RMD9 deletion both confer defective mitochondrial function and accelerated aging, whereas YBR238C deletion and RMD9 overexpression enhance mitochondrial function and longevity . To investigate this relationship using antibodies:

• Co-immunoprecipitation studies: Develop antibodies against both YBR238C and RMD9 to investigate whether they interact directly or compete for the same binding partners or RNA targets. This could elucidate whether their antagonistic effects result from direct competition or through independent pathways.

• Chromatin Immunoprecipitation (ChIP) analysis: If YBR238C influences transcription factors like HAP4, ChIP studies using antibodies against these factors could reveal how YBR238C and RMD9 differentially affect transcriptional networks regulating mitochondrial genes.

• RNA Immunoprecipitation (RIP): Since both proteins contain pentatricopeptide repeat domains associated with RNA binding, RIP analysis could identify potentially different or overlapping RNA targets that explain their opposing effects .

• Proteomics of isolated complexes: Immunoprecipitation of YBR238C and RMD9 followed by mass spectrometry could identify unique and shared interaction partners that contribute to their antagonistic functions.

A comprehensive investigation would require controlled expression systems (deletion strains, overexpression constructs) combined with antibody-based detection methods to track changes in complex formation and downstream effects on mitochondrial function .

What are the optimal conditions for detecting YBR238C protein expression changes in aging studies?

Optimal detection of YBR238C protein expression changes in aging studies requires careful consideration of several factors:

When designing aging experiments to track YBR238C expression, researchers should consider that YBR238C regulates lifespan through both HAP4-dependent and HAP4-independent mechanisms . Therefore, parallel tracking of HAP4 expression and activity would provide valuable context. Additionally, monitoring mitochondrial function markers (ATP levels, ROS production, oxygen consumption) alongside YBR238C expression would help correlate protein levels with phenotypic outcomes .

How should researchers approach epitope mapping for YBR238C antibody development?

Effective epitope mapping for YBR238C antibody development requires strategic targeting of protein regions that balance antigenicity, specificity, and functional relevance:

• Structural analysis: The YBR238C protein contains an intrinsically unstructured N-terminal region (~130 residues) and a pentatricopeptide repeat region (residues 130-675) . Focus epitope selection on the more structured regions to improve antibody quality.

• Paralog distinction: To prevent cross-reactivity with the paralog RMD9, align both protein sequences and identify regions with minimal homology. These unique regions represent prime targets for specific antibody development.

• Functional domains: If investigating YBR238C function, develop antibodies against the pentatricopeptide repeat region, which likely mediates RNA-binding activities similar to RMD9 .

• Epitope accessibility: Consider the native conformation of YBR238C in the mitochondria when selecting epitopes, as some regions may be obscured in the folded protein or through interaction with binding partners.

A recommended approach is to develop a panel of antibodies targeting different regions of YBR238C, then validate each for specificity against wild-type and ybr238cΔ strains under various experimental conditions . This multi-epitope strategy increases the likelihood of obtaining antibodies suitable for different applications (Western blotting, immunoprecipitation, immunofluorescence).

How can researchers resolve conflicting results when studying YBR238C function?

Conflicting results in YBR238C research can arise from several sources, as evidenced by the contradictory annotations in SGD regarding its effects on replicative lifespan . To resolve such discrepancies:

• Strain background effects: Use multiple yeast backgrounds (e.g., BY4743 and CEN.PK as used in the primary research) to ensure findings are not strain-specific . Compare experimental outcomes across different genetic backgrounds systematically.

• Methodological variations: Employ multiple methodologies to assess the same parameter. For CLS studies, researchers have validated findings using three different outgrowth survival methods to strengthen confidence in results .

• Environmental conditions: Control for growth phase, media composition, and temperature, as these factors can significantly impact YBR238C expression and function. Small variations in culture conditions can lead to contradictory outcomes in aging studies.

• Expression level considerations: Since both deletion and overexpression of YBR238C affect lifespan and mitochondrial function in opposite ways , carefully titrate expression levels in complementation studies to avoid artifacts from non-physiological expression.

• Genetic interaction analysis: When conflicting results appear, examine genetic interactions with known partners (HAP4, RMD9) to determine whether the contradictions arise from compensatory mechanisms or context-dependent effects .

A systematic approach using standardized conditions across multiple methodologies and genetic backgrounds will help resolve conflicting results and establish consensus on YBR238C function.

What are the best practices for validating YBR238C antibody specificity in experimental systems?

Rigorous validation of YBR238C antibody specificity is crucial for reliable experimental outcomes, especially given the presence of its paralog RMD9 and the generally uncharacterized nature of the protein . Best practices include:

• Genetic validation: Test the antibody against samples from wild-type, ybr238cΔ, and YBR238C-overexpression strains to confirm signal specificity . The antibody should show no signal in knockout strains and increased signal in overexpression strains.

• Epitope competition assays: Pre-incubate the antibody with the peptide used for immunization to demonstrate that this blocks specific binding in subsequent applications.

• Cross-reactivity assessment: Test against rmd9Δ strains and RMD9-overexpression strains to ensure the antibody does not detect the paralog .

• Multiple antibody concordance: Develop antibodies against different epitopes of YBR238C and verify that they yield consistent results across applications.

• Application-specific validation: Validate the antibody separately for each intended application (Western blotting, immunoprecipitation, immunofluorescence), as an antibody may perform well in one application but not others.

Document the validation process thoroughly, including details of positive and negative controls, to establish confidence in antibody specificity before proceeding with experimental applications.

How might YBR238C antibodies contribute to understanding the TORC1-Mitochondria-TORC1 (TOMITO) signaling process?

The recently described TORC1-Mitochondria-TORC1 (TOMITO) signaling process represents a feedback loop where TORC1 regulates mitochondrial function through effectors like YBR238C, and mitochondrial function in turn modulates TORC1 activity . YBR238C-specific antibodies could advance understanding of this pathway through:

• Dynamic interaction studies: Tracking YBR238C protein complexes under different metabolic states (high vs. low TORC1 activity) to identify condition-specific interaction partners mediating mitochondrial regulation.

• Phosphoproteomics: Combining immunoprecipitation with phosphoproteomic analysis to determine if YBR238C is directly phosphorylated by TORC1 or its downstream kinases, potentially revealing regulatory mechanisms.

• Spatial organization: Using super-resolution microscopy with YBR238C antibodies to visualize its precise localization within mitochondrial subcompartments and how this changes during TOMITO signaling.

• Translation to mammalian systems: Developing antibodies against potential mammalian homologs or functional equivalents of YBR238C to investigate conservation of the TOMITO pathway in higher eukaryotes, with implications for human aging and disease.

These approaches could elucidate how YBR238C connects TORC1 signaling to mitochondrial function, potentially identifying novel therapeutic targets for age-related diseases characterized by mitochondrial dysfunction .

What experimental approaches using YBR238C antibodies could help characterize its RNA-binding activities?

Based on sequence homology with its paralog RMD9 and the presence of a pentatricopeptide repeat region, YBR238C likely functions as an RNA-binding protein . To characterize these activities using antibodies:

• RNA Immunoprecipitation followed by sequencing (RIP-seq): Use YBR238C antibodies to immunoprecipitate the protein along with its bound RNAs, followed by high-throughput sequencing to identify its RNA targets. Compare these with RMD9 targets to understand their functional divergence.

• Cross-linking and Immunoprecipitation (CLIP): Apply techniques like CLIP-seq to precisely map YBR238C binding sites on target RNAs, revealing sequence or structural motifs recognized by the protein.

• In vitro RNA binding assays: Combine recombinant YBR238C protein with candidate RNA targets identified through genomic approaches, using techniques like electrophoretic mobility shift assays (EMSA) to confirm direct binding and measure affinity.

• Structure-function analysis: Develop domain-specific antibodies to determine which regions of YBR238C are essential for RNA binding and how these compare to equivalent domains in RMD9.

• Conditional depletion studies: Use antibodies to track changes in target RNA stability, localization, or translation efficiency following conditional depletion of YBR238C, revealing the functional consequences of its RNA-binding activities.

Understanding the RNA-binding profile of YBR238C would provide crucial insights into how it regulates mitochondrial function and cellular aging at the post-transcriptional level .